For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaceutical research company Pharmaxis Ltd (ASX: PXS), the leading developer of therapeutics targeting lysyl oxidase enzymes to treat fibrosis and cancer, announced it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for a planned phase 1/2 study of PXS-5505 for the treatment of myelofibrosis. The protocol incorporates a one-month dose escalation phase followed by 6 months’ treatment in an open label study of patients who are not on a JAK inhibitor. The study is planned to commence in Q4 2020 and expected to conclude in 2022.Read full media release - pdf
Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced that the U.S. Food & Drug Administration (FDA) has granted orphan-drug designation for its oral pan LOX inhibitor PXS-5505 for the treatment of myelofibrosis.Read full media release - pdf
Pharmaxis Ltd (ASX: PXS) chief executive officer Mr Gary Phillips will present at the Monsoon Communications Webinar on Wednesday 3 June 2020 at 11:00am AEST. The webinar will be hosted by David Blake, publisher of Bioshares and will feature presentations by Mr Phillips and Opthea CEO & Managing Director Dr Megan Baldwin.
Shareholders and investors are invited to participate in this free event.
The event is free and investors should register in advance to participate using the following registration link: